Frontlight ResearchEarly access
Not yet recruitingPhase 4
A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa originator) and Human Chorionic Gonadotropin (hCG) in Enhancing Sperm Concentration in Men with Oligozoospermia, Low Testosterone, and Normai FSH Serum Levels (APHRODITE Group 3): A Collaborative Research Initiative
Key facts
- Who runs it
- Martin-Luther-Universitaet Halle-Wittenberg
- Where
- Germany, Italy, and Spain7 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 138 people, planned
- Started
- 28 Feb 2026
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional
- Record updated
- 25 May 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Male with an age ≥ 18 years old ≤ 55 years old
- BMI < 35 kg/m2
- Male infertility of at least 12 months (ICMART definition)
- Sperm concentration ≥ 1 million/ml and ≤ 16 million/ml at screening
- Normal FSH serum levels (1.5-8 IU/mL) at screening
- Normal LH serum levels (at least 1.5 IU/ml) at screening
- Low testosterone serum levels (between 210 and 350 ng/dL, corresponding to 7.3-12.1nmol/L) at screening
- Normal serum prolactin and thyroid-stimulating hormone (TSH) values as measured in a local lab
- Have not received gonadotropin, aromatase inhibitors and SERMs at least 3 months before the start of screening
- No clinically significant abnormal findings in the screening haematology, biochemistry, and urinalysis parameters
Who cannot take part
- Patients that received testosterone therapy at any time during the previous 12 months of the study screening
- Signs of testicular inflammation and or infection, as well as signs of obstruction (including testicular volume higher than 25 mL at ultrasound examination)
- At Screening and during the study period the presence of an uncontrolled chronic disease (ongoing acute episodes or inadequate treatments), such as diabetes mellitus, thyroid disorders, autoimmune diseases such as arthritis, vasculitis or inflammatory bowel disease
- Presence of active malignancies
- Patients with history of gonadotoxic treatments
- Patients with a history of anabolic steroid use
- Diagnosed genetic mutations responsible for abnormal sperm concentration (e.g., YCMD, CFTR gene mutations)
- Patients with clinical varicocele (any grade)
- Patients with one testis
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where is this trial?
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess the impact of the combined administration of r-hFSH-alfa originator plus hCG compared to no treatment on sperm concentration in men with lowered semen analysis, low testosterone serum levels and normai FSH serum levels.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa originator) and Human Chorionic Gonadotropin (hCG) in Enhancing Sperm Concentration in Men with Oligozoospermia, Low Testosterone, and Normal FSH Serum Levels (APHRODITE Group 3): A Collaborative Research Initiative
- Criteria questions
- Built from 2025-525005-20-00, who can take part
- Record updated
- 25 May 2026